Lilly sues over black-market retatrutide; Neurocrine's new obesity drug linked to patient deaths

Eli Lilly has filed six lawsuits against U.S. companies it says are illegally selling black-market versions of its experimental obesity drug retatrutide. The company alleges the defendants are distributing the drug without authorization and is seeking damages for the alleged wrongdoing.

The lawsuits highlight ongoing challenges around the control of experimental therapies and the potential for unauthorized distribution in the market.

Separately, a group of physicians and experts in Prader-Willi syndrome have alerted clinicians to a series of patient deaths and severe side effects that may be associated with Vykat XR, a newly approved drug from Neurocrine Biosciences.

The safety concerns have prompted warnings to healthcare providers as they monitor patients using the newly approved medication.

Both stories underscore the importance of vigilant oversight in drug development, approval, and post‑market surveillance.